In line with its 40th anniversary initiatives, Galderma has relaunched its collagen stimulating injectable Sculptra in Europe.
The PLLA (poly-L-lactic acid) product has a new administration protocol which allows for faster reconstitution, updated for practitioner convenience. In addition, clinicians now have the option of adding lidocaine to the solution for increased patient comfort.
Whereas previously practitioners had to wait two hours following reconstitution to administer the product, Sculptra can now be used immediately following a two-minute reconstitution, giving it the fastest preparation protocol of any PLLA filler available in Europe, according to Galderma.
Data from new physiochemical studies provided the basis for the updated protocol, as well as results from a randomised, evaluator-blinded, parallel-group, multi-centre study evaluating the safety and effectiveness of two different dilutions of Sculptra.
The study demonstrated that treatment immediately following a two-minute reconstitution using the higher reconstitution volume (9ml including lidocaine) was well tolerated, caused less pain on injection and was comparable to that of the reference group (Sculptra5ml) in reducing wrinkle severity of nasolabial folds.
Sculptra works to gradually revitalise the skin’s structural foundation, providing results for up to 25 months. The product is suitable for increasing the volume of depressed areas, particularly to correct skin depressions such as skin creases, wrinkles, folds, scars and for skin ageing. It is also suitable for large volume corrections of the signs of facial fat loss. Sculptra was first approved in Europe in 1999.
To mark the relaunch Galderma held an interactive virtual launch event which was attended by over 1,000 healthcare professionals and media representatives from around the world, where training and best practice was shared among physicians based on their clinical experiences.
“We are delighted to bring this expanded Sculptra offering to healthcare professionals in Europe, and [the] launch event was an exciting, well-attended re-introduction to Sculptra and Galderma’s larger aesthetics portfolio,” said Alexandre Brennan, global business unit head of Galderma Aesthetics.
“We continue to build a unique and extensive aesthetics offering at Galderma, and are proud to re-launch Sculptra in Europe as the foundation of our portfolio alongside a range of complementary treatments to deliver impressive and long-lasting results for healthcare professionals and their patients.”
To coincide with the relaunch the company is utilising its Galderma Aesthetic Injector Network (GAIN) for Sculptra clinical training and mentor support. The GAIN programme includes Galderma Academies, masterclasses, congress engagements, injector training tools, and programs to develop key external experts.
Galderma recieved FDA approval for its Restylane Kysse HA filler in May last year.
